Global Longlife Hospital & Research (BOM:543520) Other Stockholders Equity: ₹6.59 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543520 Global Longlife Hospital & Research Ltd BOM:543520
37 GF Score
Price ₹10.55
GF Value ₹1.37
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Global Longlife Hospital & Research Other Stockholders Equity?

Global Longlife Hospital & Research BOM:543520 +3.63% 37 Other Stockholders Equity is ₹6.59 Mil as of Mar. 2026. GuruFocus rates BOM:543520 with a GF Score™ of 37/100 and a GF Value™ of ₹1.37 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Global Longlife Hospital & Research's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹6.59 Mil.

Global Longlife Hospital & Research's quarterly Other Stockholders Equity increased from Mar. 2025 (₹6.59 Mil) to Sep. 2025 (₹149.65 Mil) but then declined from Sep. 2025 (₹149.65 Mil) to Mar. 2026 (₹6.59 Mil).

Global Longlife Hospital & Research's annual Other Stockholders Equity increased from Mar. 2024 (₹0.00 Mil) to Mar. 2025 (₹6.59 Mil) but then declined from Mar. 2025 (₹6.59 Mil) to Mar. 2026 (₹6.59 Mil).

Global Longlife Hospital & Research Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Global Longlife Hospital & Research's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Global Longlife Hospital & Research Other Stockholders Equity Chart

Global Longlife Hospital & Research Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial 41.10 41.10 0.00 6.59 6.59

Global Longlife Hospital & Research Semi-Annual Data
Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 166.70 6.59 149.65 6.59
BOM:543520
37GF Score
Global Longlife Hospital & Research Ltd BOM:543520
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Global Longlife Hospital & Research Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹6.59 Mil mean?
Global Longlife Hospital & Research (BOM:543520) has a Other Stockholders Equity of ₹6.59 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Global Longlife Hospital & Research and its competitors.
Is Global Longlife Hospital & Research's Other Stockholders Equity too high?
Global Longlife Hospital & Research's current Other Stockholders Equity is ₹6.59 Mil. Overall, Global Longlife Hospital & Research has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Global Longlife Hospital & Research's Other Stockholders Equity compare to HCA and THC?
Global Longlife Hospital & Research's Other Stockholders Equity of ₹6.59 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Healthcare Providers & Services company?
A good Other Stockholders Equity depends on the Healthcare Providers & Services industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Global Longlife Hospital & Research and its competitors. Global Longlife Hospital & Research's current Other Stockholders Equity is ₹6.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Global Longlife Hospital & Research stock overvalued right now?
Based on GuruFocus' analysis, Global Longlife Hospital & Research (BOM:543520) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1.37, compared to a current price of ₹10.55 — trading 670.1% above its estimated fair value. The current Other Stockholders Equity is ₹6.59 Mil. Global Longlife Hospital & Research's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Global Longlife Hospital & Research (BOM:543520), the current Other Stockholders Equity is ₹6.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Global Longlife Hospital & Research (BOM:543520) Overvalued in 2026?

Based on GuruFocus' analysis, Global Longlife Hospital & Research stock appears to be overvalued. The current stock price of ₹10.55 is trading 670.1% above its estimated GF Value™ of ₹1.37. GuruFocus considers Global Longlife Hospital & Research to be Significantly Overvalued.

Key valuation signals for BOM:543520:

  • Other Stockholders Equity: ₹6.59 Mil
  • GF Value™: ₹1.37 vs. price of ₹10.55 (670.1% above fair value)
  • GF Score™: 37/100 with 1 warning sign

No single metric tells the full story. See the BOM:543520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Global Longlife Hospital & Research Business Description

Address Sindhu Bhavan Road, Beside Taj Skyline, 703, Sankalp Square, 3B, Ahmedabad, GJ, IND, 380 059
Global Longlife Hospital & Research Ltd is Multispecialty Hospital providing Medical & Allied Services. The company operates in the single segment i.e. Health Care and Hospital. Its services are Medical, Surgical, Radiology, Pathology, and Other Services.
37GF Score

Get the complete analysis for BOM:543520

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹10.55
Price
₹1.37
GF Value